Abstract
Use of animal products to culture human stem cells poses risk of pathogens and other contaminations which may render stem cells therapeutically unsuitable. Hence, it is necessary to meet the standards of good manufacturing practices, clinical-grade like and xeno-free conditions. The protocol for culturing clinical grade stem cells needs to be modified so that maximum utilization can be done for stem cell therapies. Modifications can be in the media compositions, additional growth factors, small molecule compounds, and gene manipulations of the required transcription factors or the platform in which stem cells can grow. After the clinical grade standards are met it needs the approval of FDA for use as transplantation therapies. This review provides various methods and inventions for culturing clinical grade stem cells which have been patented.
Keywords: Clinical grade, cytokines, embryonic stem cells, growth factors, induced pluripotent stem cells, matrix, mesenchymal stem cells, stem cells, xeno-free.
36